A Phase 2 Master Protocol to Assess the Efficacy and Safety of FORE8394, an Inhibitor of BRAF Class 1 and Class 2 Alterations, in Participants With Cancer Harboring BRAF Alterations
A Phase 2 Master Protocol to Assess the Efficacy and Safety of FORE8394, an Inhibitor of BRAF Class 1 and Class 2 Alterations, in Participants With Cancer Harboring BRAF Alterations
NCT #
NCT05503797
Condition(s)
Central Nervous System Tumor, Glioma
Molecular Target(s)
BRAF
Drug Classification(s)
n/a
Agents(s)
solid tumor
Phase(s)
II
Mechanism of Action
n/a
Purpose
n/a
- Group A:
- Male and female, ≥10 years of age, and weighing ≥30 kg.
- Histologic diagnosis of a solid tumor or primary CNS tumor.
- Documentation of BRAF gene fusion in tumor and/or blood detected by an analytically validated test by DNA sequencing or RNA (transcriptome) sequencing.
- Have an archival tissue sample available with sufficient tumor for central next generation sequencing (NGS) testing and biomarker analyses. If an archival tissue sample is not available, a newly obtained (before treatment) tumor biopsy may be submitted instead.
- Consent to provide scan(s) prior to baseline to assess change in tumor trajectory (at least 2 preferred). For participants with LGG, every effort should be made to provide 3 to 4 pre-baseline scans to the central imaging vendor whenever feasible.
- Received at least available standard therapy, is intolerant to available therapies, or the investigator has determined that treatment with standard therapy is not appropriate.
- All adverse events related to prior therapies (chemotherapy; radiotherapy; surgery) must have resolved to Grade 1 or baseline except for
- Alopecia (Grade ≤2)
- Sensory neuropathy (Grade ≤2)
- Other adverse events that have resolved to Grade ≤2 that, according to the clinical judgment of the investigator, do not constitute a safety risk to the participant.
- Group B:
- Male and female, ≥10 years of age, and weighing ≥30 kg.
- Histological diagnosis of a grade 3 or 4 glioma or glioneuronal tumor (including glioblastoma, anaplastic astrocytoma, high grade astrocytoma with piloid features, pilocytic astrocytoma, gliosarcoma, anaplastic pleomorphic xanthoastrocytoma, anaplastic oligodendroglioma, anaplastic oligoastrocytoma, not otherwise specified [NOS], or high grade ganglioglioma), or has a prior, histologically confirmed, diagnosis of a grade 2 glioma and now has radiographic or histopathological findings consistent with an HGG (World Health Organization [WHO][2021] grade 3 or 4).
- Note: If a non anaplastic pleomorphic xanthoastrocytoma is re-resected at recurrence and found to have a ≥ Grade 2 histology, this would be considered eligible.
- Have received at least one line of prior therapy including radiation. NOTE: Patients for whom radiotherapy is not considered standard of care may remain eligible for the study.
- Documented BRAF V600E mutation in tumor and/or blood (if individual test has sufficient analytical coverage) detected by an analytically validated test by NGS or polymerase chain reaction (PCR) methods.
- An archival tissue sample at less than 24 months from date of screening or >24 months if the participant has never received a targeted therapy, or fresh biopsy is required if the archival sample is not available for retrospective confirmation test. Tissue obtained most proximal to initiating this basket trial is preferred.
- Measurable disease based upon RANO HGG as determined by the radiographic BICR.
- All adverse events related to prior therapies (eg, chemotherapy, radiotherapy, surgery) must have resolved to Grade 1 or baseline except for:
- Alopecia (Grade ≤2)
- Sensory neuropathy (Grade ≤2)
- Other adverse events that have resolved to Grade ≤2 that, according to the clinical judgment of the investigator, do not constitute a safety risk to the participant
- Participants who are receiving corticosteroid treatment must be on a stable or decreasing dose of ≤8 mg/day of dexamethasone or equivalent corticosteroid treatment for 7 days prior to first dose of study treatments.
- Group A:
- Participants with known co-occurring NF1 alteration and/or RAS-related mutations.
- Participants with evidence of subclonal mutations or heterogeneity that are indicative of a prior treatment effect instead of a driver mutation.
- Prior treatment with RAF/BRAF inhibitors active for Class 2 BRAF alterations for advanced unresectable or metastatic disease (such as tovorafenib [formerly known as DAY 101, TAK 580, and MLN 2480], KIN-2787, BGB-3245, and CFT1946).
- Prior treatment with a MEK inhibitor.
- Tyrosine kinase inhibitor(s) and/or targeted therapies are allowed (other than BRAF/MAPK pathway inhibitors per Exclusion Criteria 3 and 4) and will be restricted to no more than the number of lines of therapy that are consistent with standard treatment guidelines. NOTE: There is no restriction on the number of lines of chemotherapy or immunotherapy.
- Malignancy with co-occurring activating RAS mutation(s) at any time.
- Uncontrolled intercurrent illness that would limit compliance with study requirements.
- Current or planned participation in a study of an investigational agent or device.
- Have impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral FORE8394 or cobicistat (such as ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, and small bowel resection).
- Are currently receiving (within 7 days of Cycle 1 Day 1) or are planning to receive during participation:
- Agents that are known strong inducers or inhibitors of CYP3A4 (other than cobicistat). Restrictions include foods or herbal medications, including grapefruit juice and grapefruit/grapefruit related citrus fruits (eg, Seville oranges, pomelos), and St. John’s Wort.
- Agents that are contraindicated with cobicistat. Note: For participants with no other option except agents with potential drug interactions with cobicistat, but which are not contraindicated, the dose of that agent must be altered or the regimen must follow the cobicistat prescribing information and be approved by the medical monitor.
- Group B:
- Prior treatment with BRAF, ERK, and/or MEK inhibitor(s).
- Known or suspected neurofibromatosis-1 (NF-1) and/or Ras related gene alterations.
- Uncontrolled intercurrent illness that would limit compliance with study requirements.
- Active infection requiring systemic therapy.
- Current or planned participation in a study of an investigational agent or device.
- Have impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of oral FORE8394 or cobicistat (such as ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, small bowel resection).
- Are currently receiving (within 7 days of Cycle 1 Day 1) or are planning to receive during participation:
- Agents that are known strong inducers or inhibitors of CYP3A4 (other than cobicistat). Restrictions include foods or herbal medications, including grapefruit juice, grapefruit/grapefruit related citrus fruits (eg, Seville oranges, pomelos), and St. John’s Wort.
- Agents that are contraindicated with cobicistati)
- For participants with no other option except agents with potential drug interactions with cobicistat, but which are not contraindicated, the dose of that agent must be altered or the regimen must follow the cobicistat prescribing information and be approved by the medical monitor.
Excludes RAF/BRAF inhibitors active for Class 2 BRAF alterations
Location
MCD
Similar Trials
Discover more trials like this.
Trial Number
Mechanism of Action
Drug Classifications
Target Required
Conditions
Site
F8394-201
n/a
n/a
BRAF gene fusion
Central Nervous System Tumor, Glioma
MCD
Connect With Us
Whether you want to give a spark of hope or you are looking for it, we are here to help. If you have any questions or concerns, please contact us here.